CG
PTGX icon

Caprock Group’s Protagonist Therapeutics PTGX Stock Holding History

Caprock Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,991
Closed -$523K – 1258
2025
Q4 		$523K Buy
5,991
+189
+3% +$15.5K 0.01% 803
2025
Q3 		$343K Buy
+5,802
New +$330K 0.01% 907
2025
Q1 		$285K Buy
5,890
+88
+2% +$3.69K 0.01% 885
2024
Q4 		$224K Buy
+5,802
New +$253K 0.01% 906

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Caprock Group's PTGX Position: Q1 2026 in Review

Caprock Group sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 5,991 shares — an estimated $523K sold.

Caprock Group first reported a position in PTGX in Q4 2024 and held it in 4 quarters. The position peaked at $523K in Q4 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Caprock Group reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Caprock Group sold 5,991 Protagonist Therapeutics shares in Q1 2026, an estimated $523K.
  • Caprock Group first reported a position in Protagonist Therapeutics in Q4 2024 and held it in 4 quarters.
  • Caprock Group's Protagonist Therapeutics position peaked at $523K in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Caprock Group's 13F filing for Q1 2026, filed 11 May 2026.